Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases

Leukemia

Volumn 26, Issue 7, 2012, Pages 1693-1695

  Lierman, E ^a,c   Smits, S ^a   Cools, J ^a,b   Dewaele, B ^c   Debiec Rychter, M ^a,c   Vandenberghe, P ^a,c  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b CME VIB11 ^*  (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CUX1 PROTEIN; DOVITINIB; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIP1 LIKE 1 PROTEIN; IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PONATINIB; PROTEIN; STEM CELL FACTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; AUTOPHOSPHORYLATION; CANCER INHIBITION; CELL GROWTH; CELL STRAIN; FUSION GENE; GENE EXPRESSION; IC 50; IN VITRO STUDY; LETTER; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; WESTERN BLOTTING; WILD TYPE;

EID: 84863782614     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.8     Document Type: Letter

References (15)

1. O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009; 16: 401-412.
2. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348: 1201-1214.
3. Gotlib J, Cools J. Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. Leukemia 2008; 22: 1999-2010.
4. Metzgeroth G, Erben P, Martin H, Mousset S, Teichmann M, Walz C et al. Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation. Leukemia 2012; 26: 162-164.
5. Score J, Walz C, Jovanovic JV, Jones AV, Waghorn K, Hidalgo-Curtis C et al. Detection and molecular monitoring of FIP1L1-PDGFRA-positive disease by analysis of patient-specific genomic DNA fusion junctions. Leukemia 2009; 23: 332-339.
6. Stover EH, Chen J, Lee BH, Cools J, McDowell E, Adelsperger J et al. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. Blood 2005; 106: 3206-3213.
7. Lierman E, Michaux L, Beullens E, Pierre P, Marynen P, Cools J et al. FIP1L1-PDGFRalpha D842 V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib. Leukemia 2009; 23: 845-851.
8. Cross NC, Reiter A. Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders. Acta Haematol 2008; 119: 199-206.
9. Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, van Oosterom AT et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006; 42: 1093-1103.
10. Gozgit JM, Wong MJ, Wardwell S, Tyner JW, Loriaux MM, Mohemmad QK et al. Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Mol Cancer Ther 2011; 10: 1028-1035.
11. Wasag B, Lierman E, Meeus P, Cools J, Vandenberghe P. The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11). Haematologica 2011; 96: 922-926.
12. von Bubnoff N, Gorantla SP, Engh RA, Oliveira TM, Thone S, Aberg E et al. The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro. Oncogene 2011; 30: 933-943.
13. Prenen H, Cools J, Mentens N, Folens C, Sciot R, Schoffski P et al. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res 2006; 12: 2622-2627.
14. Guo T, Agaram NP, Wong GC, Hom G, D'Adamo D, Maki RG et al. Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clin Cancer Res 2007; 13: 4874-4881.
15. Zhou T, Commodore L, Huang WS, Wang Y, Thomas M, Keats J et al. Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. Chem Biol Drug Des 2011; 77: 1-11.